ARTICLE | Finance
HAE maker
Why Shire thinks it's done buying assets in HAE
November 9, 2015 8:00 AM UTC
The $10.5 billion shopping spree by Shire plc (LSE:SHP; NASDAQ:SHPG) in hereditary angioedema likely has come to an end, as the company expects it now has all the HAE products it needs.
The final deal came last week, when Shire announced plans to buy Dyax Corp. (NASDAQ:DYAX) for $5.9 billion in cash, or $37.30 per share. The driver is DX-2930, a mAb against plasma kallikrein expected to start Phase III testing this quarter to prevent HAE attacks. ...